Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.

Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ.

Am J Clin Oncol. 2011 Oct;34(5):454-9. doi: 10.1097/COC.0b013e3181f47aa4.

2.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ.

Ann Oncol. 2014 Mar;25(3):663-8. doi: 10.1093/annonc/mdt578. Epub 2014 Jan 23.

3.

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.

Bracarda S, Iacovelli R, Boni L, Rizzo M, Derosa L, Rossi M, Galli L, Procopio G, Sisani M, Longo F, Santoni M, Morelli F, Di Lorenzo G, Altavilla A, Porta C, Camerini A, Escudier B; Rainbow Group.

Ann Oncol. 2015 Oct;26(10):2107-13. doi: 10.1093/annonc/mdv315. Epub 2015 Jul 27. Erratum in: Ann Oncol. 2016 Feb;27(2):366.

PMID:
26216384
4.

Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma.

Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM.

Am J Clin Oncol. 2013 Oct;36(5):450-4. doi: 10.1097/COC.0b013e3182546a91.

5.

Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.

Tirumani SH, Souza D, Krajewski KM, Jagannathan JP, Ramaiya NH, Shinagare AB.

Abdom Radiol (NY). 2016 Feb;41(2):295-302. doi: 10.1007/s00261-015-0569-7.

PMID:
26867911
6.

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

Keizman D, Ish-Shalom M, Pili R, Hammers H, Eisenberger MA, Sinibaldi V, Boursi B, Maimon N, Gottfried M, Hayat H, Peer A, Kovel S, Sella A, Berger R, Carducci MA.

Eur J Cancer. 2012 May;48(7):1031-7. doi: 10.1016/j.ejca.2012.02.050. Epub 2012 Mar 10.

PMID:
22409947
7.

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

Choueiri TK, Plantade A, Elson P, Negrier S, Ravaud A, Oudard S, Zhou M, Rini BI, Bukowski RM, Escudier B.

J Clin Oncol. 2008 Jan 1;26(1):127-31. doi: 10.1200/JCO.2007.13.3223.

PMID:
18165647
8.

SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.

Eichelberg C, Vervenne WL, De Santis M, Fischer von Weikersthal L, Goebell PJ, Lerchenm├╝ller C, Zimmermann U, Bos MM, Freier W, Schirrmacher-Memmel S, Staehler M, Pahernik S, Los M, Schenck M, Fl├Ârcken A, van Arkel C, Hauswald K, Indorf M, Gottstein D, Michel MS.

Eur Urol. 2015 Nov;68(5):837-47. doi: 10.1016/j.eururo.2015.04.017. Epub 2015 May 4.

9.

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma.

Molina AM, Feldman DR, Ginsberg MS, Kroog G, Tickoo SK, Jia X, Georges M, Patil S, Baum MS, Reuter VE, Motzer RJ.

Invest New Drugs. 2012 Feb;30(1):335-40. doi: 10.1007/s10637-010-9491-6. Epub 2010 Aug 14.

10.

Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.

Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E.

Oncology. 2007;73(3-4):204-9. doi: 10.1159/000127387. Epub 2008 Apr 16.

PMID:
18418013
11.

Targeted Therapy for Renal Cell Carcinoma.

Joshi R, Rawal S.

JNMA J Nepal Med Assoc. 2015 Apr-Jun;53(198):83-8.

PMID:
26994026
12.

Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.

Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin S, Swanson DA, Wood CG.

J Urol. 2007 Nov;178(5):1896-900. Epub 2007 Sep 17.

PMID:
17868729
13.

A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.

Tagawa ST, Milowsky MI, Jeske S, Mazumdar M, Kung S, Sung M, Lehrer D, Matulich D, Selzer J, Wright JJ, Nanus DM.

Am J Clin Oncol. 2011 Oct;34(5):443-8. doi: 10.1097/COC.0b013e3181e9c0d7.

PMID:
20881475
14.

Sarcomatoid renal cell carcinoma: clinical outcome and survival after treatment with sunitinib.

Kunene V, Miscoria M, Pirrie S, Islam MR, Afshar M, Porfiri E.

Clin Genitourin Cancer. 2014 Aug;12(4):251-5. doi: 10.1016/j.clgc.2013.12.001. Epub 2013 Dec 27.

PMID:
24560086
15.

Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

Golshayan AR, George S, Heng DY, Elson P, Wood LS, Mekhail TM, Garcia JA, Aydin H, Zhou M, Bukowski RM, Rini BI.

J Clin Oncol. 2009 Jan 10;27(2):235-41. doi: 10.1200/JCO.2008.18.0000. Epub 2008 Dec 8.

PMID:
19064974
16.

Sarcomatoid features, necrosis, and grade are prognostic factors in metastatic clear cell renal cell carcinoma with vascular endothelial growth factor-targeted therapy.

Park JY, Lee JL, Baek S, Eo SH, Go H, Ro JY, Cho YM.

Hum Pathol. 2014 Jul;45(7):1437-44. doi: 10.1016/j.humpath.2014.02.019. Epub 2014 Mar 6.

PMID:
24784922
17.

Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component.

Park I, Cho YM, Lee JL, Ahn JH, Lee DH, Song C, Hong JH, Kim CS, Ahn H.

J Cancer Res Clin Oncol. 2013 May;139(5):817-27. doi: 10.1007/s00432-013-1386-4. Epub 2013 Feb 9. Erratum in: J Cancer Res Clin Oncol. 2013 Oct;139(10):1777-9.

PMID:
23397357
18.

Long-term response to sunitinib therapy for metastatic renal cell carcinoma.

Molina AM, Jia X, Feldman DR, Hsieh JJ, Ginsberg MS, Velasco S, Patil S, Motzer RJ.

Clin Genitourin Cancer. 2013 Sep;11(3):297-302. doi: 10.1016/j.clgc.2013.04.001. Epub 2013 May 24.

19.

A phase II trial of doxorubicin and gemcitabine in renal cell carcinoma with sarcomatoid features: ECOG 8802.

Haas NB, Lin X, Manola J, Pins M, Liu G, McDermott D, Nanus D, Heath E, Wilding G, Dutcher J.

Med Oncol. 2012 Jun;29(2):761-7. doi: 10.1007/s12032-011-9829-8. Epub 2011 Feb 6.

20.

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY.

Eur Urol. 2015 Sep;68(3):506-15. doi: 10.1016/j.eururo.2014.11.054. Epub 2014 Dec 15.

PMID:
25524810

Supplemental Content

Support Center